The Texas A&M University System

Inhibitex, Inc.

Other

The University of Texas System

The UAB Research Foundation (The University of Alabama at Birmingham)

Universitá Degli Studi Di Pavia

The University of Alabama

The Provost Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth, Near Dublin

Technische Universitat Braunschweig

Ecm Technologies

The Provost Fellows and Scholars of the College of the Holy and Undivived Trinity of Queen Elizabeth Near Dublin

The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth, Near Dublin

Magnus A Hook

Joseph M Patti

Timothy James Foster

Brooke Hageman Russell

Elizabeth L Cosgriff-Hernandez

Jeff T Hutchins

Yi Xu

Neungseon Seo

Andrea Hall

Mariah S Hahn

Maria G Bowden

Ya-Ping Ko

Marvin Xuejun Xu

Vannakambadi K Ganesh

Rick T Owens

George M Weinstock

Lawrence C Lee

Pietro Speziale

Deidre Ni Eidhin

Narayana Sthanam

Sreedhar R Nallapareddy

Barbara E Murray

Betty P Guo

Michael Hust

Xuejun Xu

Paul Domanski

Kirk McCrea

Orla Hartford

Pratiksha Patel

Jiyeun Kim

Eric L Brown

Stacy Davis

Bernd Kriekemeyer

Rebecca L Rich

Emanuel Smeds

Karthe Ponnuraj

Jouko V Sillanpaa

Jose J Rivera

Mary Beth Monroe

Srishtee Arora

Sivashankarappa Gurusiddappa

David McQuillan

Klas Jonsson

John E Volanakis

Richard Krumdieck

Livia Visal

Gabriela M Bowden

Maria Labandeira-Rey

Linda Santos

Mary Beth Browning

Doris Meier

Federico Bertoglio

Livia Visai

Fabrizia Casolini

Richard T Owens

G Maria Bowden

Karthe The Uab Research Foundation Ponnuraj

Andrea Inhibitex Inc Hall

Yi The Texas A&M Univ System Xu

Jouko V The Texas A&M Univ System Sillanpaa

Narayana The Uab Research Foundation Sthanam

Jeff T Inhibitex Inc Hutchins

Elizabeth M Cosgriff-Hernandez

The present invention includes a synthetic collagen that facilitates adhesion prevention and methods of use thereof. The present invention includes a prokaryotic collagen that facilitates adhesion prevention and treatment and methods of use thereof. The prokaryotic collagen includes an isolated and purified triple helical backbone protein that facilitates adhesion prevention: one or more alteration in a triple helical backbone protein sequence, and one or more binding motifs, wherein the isolated and purified triple helical backbone protein facilitates adhesion prevention.

Prokaryotic collagen therapeutics for postoperative adhesions

The present disclosure provides synthetic collagen and methods of making and using synthetic collagen that include a synthetic collagen that facilitates wound closure comprising an isolated and purified triple helical backbone protein that facilitates wound closure comprising one or more alteration in a triple helical backbone protein sequence, that stabilize the isolated and purified triple helical backbone protein and does not disrupt an additional collagen ligand interaction; and one or more integrin binding motifs, wherein the isolated and purified triple helical backbone protein facilitates wound closure.

Designer collagens and use thereof

The present invention provides methods and compositions to reduce binding of fibrinogen to the ClfA in a gram positive bacterial infections using monoclonal antibody, a polyclonal antibody, an antigen-binding antibody fragment or a composition that specifically binds to a portion of ClfA with the sequence of SEQ ID No: 15, SEQ ID NO: 16, SEQ ID NO: 17, and SEQ ID NO: 18.

Targeting of ligand binding sites in ClfA

The present disclosure provides methods and composition including vaccines, monoclonal antibodies, polyclonal antibodies, chimeric molecule of an extracellular fibrinogen binding protein (Efb) and targeted agent delivery pharmaceutical composition comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in inhibiting the fibrinogen binding, C3 binding, or both or administering to a subject a pharmacologically effective amount of a vaccine in a pharmaceutically acceptable excipient, comprising a modified extracellular fibrinogen binding protein comprising at least a portion of a modified N-terminus region, at least a portion of a modified C-terminus region, or both, wherein the modified extracellular fibrinogen binding protein results in not shielding the staphylococcus bacterium from recognition by a phagocytic receptor.

Compositions and use of a fibrinogen binding motif present in EFB and COA for therapeutics and vaccines against

The present invention discloses crystal structure ofClumping factor A (ClfA) in complex with fibrinogen (Fg) derived peptide. Also, the present invention also discloses the use of this structure in the design of ClfA targeted vaccines and therapeutic agents (including monoclonal antibodies). In addition, the present invention discloses isolated and purified engineeredclumping factor A protein (ClfA) with a stabilized, closed conformation and immunogenic compositions thereof including methods of treating ainfection in an individual.

Crystal structure ofclumping factor A in complex with fibrinogen derived peptide and uses thereof

The present invention identified a high affinity binding sequence in collagen type III for the collagen-binding integrin I domains. Provided herein are the methods used to characterize the sequence, the peptides comprising this novel sequence and the use of the peptides in enabling cell adhesion. Also provided herein are methods to identify specific integrin inhibitors, sequences of these inhibitors and their use in inhibiting pathophysiological conditions that may arise due to integrin-collagen interaction.

Specific binding sites in collagen for integrins and use thereof

The present invention identified a recombinant synthetic collagen containing a triple helical backbone protein produced in a prokaryotic expression system where the protein contains at least one 'inserted' biologically active sequence(s).

Monoclonal antibodies which can bind to the SdrF protein ofare provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as. The monoclonal antibodies of the invention are advantageous in that they can also recognize binding domains and subdomains of theSdrF protein in addition to the protein itself. Suitable compositions and passive vaccines based on the monoclonal antibodies of the invention, as well as methods for their use, are also provided.

[object Object]

The present invention provides a method for determining the structure of a microbial surface components recognizing adhesive matrix molecule in complex with fibrinogen, by providing a ClfA complexed with a fibrinogen gamma-peptide; determining a ClfA binding region of the fibrinogen gamma-peptide; determining one or more critical amino acid residues in the ClfA binding region of a native fibrinogen gamma-peptide that is critical for a ClfA:fibrinogen gamma-peptide interaction; determining one or more amino acid residues of the ClfA that binds to the ClfA binding region of the native fibrinogen gamma-peptide; modeling the structure of the ClfA binding region; determining the structure of the ClfA in complex with the :fibrinogen gamma-peptide interaction; and identifying one or more potential agent(s) that inhibit the ClfA:fibrinogen gamma-peptide interaction without affecting binding of other proteins to the fibrinogen gamma-peptide.

The present invention provides MSCRAMM&#xae; proteins fromwhich are putative highly-expressed antigens from methicillin-resistant, including communit-associated MRSA (CA-MRSA), and these antigens can thus be utilized in methods of generating antibodies capable of binding these antigens which can be useful in methods of treating or preventing infection from MRSA. The present invention is directed to these proteins, antibodies capable of binding these proteins, methods of generating said antibodies, nucleic acids coding for said proteins, and pharmaceutical compositions or vaccines which include the proteins or antibodies of the present invention in combination with a pharmaceutically acceptable vehicle, carrier or excipient.

Antibodies recognizing a highly expressed putative antigen of CA-MRSA and methods of use

Multicomponent vaccines are provided which aid in the prevention and treatment of staphylococcal infections and which include certain selected combinations of bacterial binding proteins or fragments thereof, or antibodies to those proteins or fragments. By careful selection of the proteins, fragments, or antibodies, a vaccine is provided that imparts protection against a broad spectrum ofand other bacterial strains and against proteins that are expressed at different stages of the logarithmic growth curve. In one embodiment of the invention, a composition is provided that includes a fibrinogen binding domain of a fibrinogen binding protein and a bacterial component such as a capsular polysaccharide, and both active and passive vaccines based on these components are also provided, along with methods of treating infection using these compositions and vaccines.

Multicomponent vaccines

A bioinformatic method for identifying and isolating proteins and peptides with MSCRAMM&#xae;-like characteristics from Gram positive bacteria, such asandbacteria, and proteins and peptides obtained thereby are provided which can be utilized in methods to prevent and treat infections caused by Gram-positive bacteria. The method involves identifying from sequence information those proteins with a putative C-terminal LPXTG (SEQ ID NO:1) cell wall sorting signal and other structural similarities to MSCRAMM&#xae; proteins having the LPXTG-anchored cell wall proteins. The MSCRAMM&#xae; proteins and immunogenic regions therein that are identified and isolated using the present invention may be useful in the diagnosis, treatment or prevention of Gram positive bacterial infections.

Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby

Multicomponent vaccines are provided which aid in the prevention and treatment of staphylococcal infections and which include certain selected combinations of bacterial binding proteins or fragments thereof, or antibodies to those proteins or fragments. By careful selection of the proteins, fragments, or antibodies, a vaccine is provided that imparts protection against a broad spectrum ofand other bacterial strains and against proteins that are expressed at different stages of the logarithmic growth curve. In one embodiment of the invention, a composition is provided that includes a fibrinogen binding domain of a fibrinogen binding protein and a bacterial component such as ca capsular polysaccharide, and both active and passive vaccines based on these components are also provided, along with methods of treating infection using these compositions and vaccines.

A collagen-binding MSCRAMM entitled Ace from enterococcal bacteria is provided which was homologous to the ligand-binding region of Cna, the collagen-binding MSCRAMM from, and which can be utilized to inhibit adhesion of enterococcal bacteria to extracellular matrix proteins. The N-terminal region of Ace contained a region (residues 174-319), or A domain, contains several 47-residue tandem repeat units between the collagen-binding site and cell wall-associated regions. The Ace protein can be utilized in methods of preventing and/or treating enterococcal infection, and in addition, antibodies raised against Ace, or its A domain, can be used to effectively inhibit the adhesion of enterococcal cells to a collagen substrate.

Collagen-binding proteins from enterococcal bacteria

Growing community of inventors

Houston, TX, United States of America

Magnus A Hook